Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD19-CAR_Lenti T cell
- Development stage
- Phase 2
- Lead developer
- Ospedale Pediatrico Bambino Gesù
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
CD19-CAR_Lenti T cell is an autologous, second-generation chimeric antigen receptor (CAR) T-cell therapy developed by the Bambino Gesù Hospital and Research Institute. The therapy consists of T cells genetically modified via a self-inactivating lentiviral vector to express a CAR targeting the CD19 antigen, which is found on the surface of B cells. The construct includes a 4-1BB costimulatory domain to enhance the persistence and anti-tumor efficacy of the infused cells. Manufactured using the automated Miltenyi CliniMACS Prodigy system, the therapy is designed for point-of-care production with a rapid vein-to-vein time of approximately 14 days. It is currently being investigated in Phase I/II clinical trials for the treatment of pediatric and young adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), diffuse large B-cell lymphoma (DLBCL), and primary mediastinal B-cell lymphoma (PML).
- Other names
- CD19-CAR_Lenti T cellautologous CD19-directed 4-1BB CAR-T cells
02
Targets
CD19 (B lymphocyte antigen CD19)TNFRSF9 (CD137 extracellular domain)
Beyond the preview
Go deeper on CD19-CAR_Lenti T cell.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD19-CAR_Lenti T cell.